Alinastine(Alinastine) - 药物靶点：H1 receptor_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Lamiakast

靶点

H1 receptor

作用机制

H1 receptor拮抗剂(组胺H1受体拮抗剂)

治疗领域

免疫系统疾病眼部疾病呼吸系统疾病+ [1]

在研适应症-

非在研适应症

哮喘变应性结膜炎皮肤疾病

原研机构

Faes Farma SA

在研机构-

非在研机构

Faes Farma SA

最高研发阶段终止临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C28H39N3O

InChIKeyNPWTVYBPSXCRPM-UHFFFAOYSA-N

CAS号154541-72-7

关联

100 项与 Alinastine 相关的临床结果

登录后查看更多信息

100 项与 Alinastine 相关的转化医学

登录后查看更多信息

100 项与 Alinastine 相关的专利（医药）

登录后查看更多信息

1

项与 Alinastine 相关的文献（医药）

1999-04-01·Journal of Chromatography B: Biomedical Sciences and Applications

Semi-automated solid-phase extraction procedure for the high-performance liquid chromatographic determination of alinastine in biological fluids

Article

作者: A Gonzalo ; B Gallo ; E Corta ; A Bakkali ; L.A Berrueta ; M.L Lucero ; F Vicente ; A Orjales

A solid-phase extraction (SPE) method for sample clean-up followed by a reversed-phase HPLC procedure for the assay of alinastina (pINN) in biological fluids is reported. The effects of the sample pH, composition of the washing and elution solvents and the nature of the SPE cartridge on recovery were evaluated. The selectivity of SPE was examined using spiked rat urine and plasma samples and the CH and PH cartridges gave rise to the cleanest extracts. The recoveries obtained in spiked rat urine and plasma samples were 91.2+/-2.7 and 99.9+/-2.8%, respectively. The proposed SPE method coupled off-line with a reserved-phase HPLC system with fluorimetric detection was applied to the quantitation of alinastine in real rat urine samples. The analytical method was also applied and validated for the determination of alinastine in dog plasma. The recovery from spiked dog plasma samples using the PH cartridge was around 65%. The within-day and between-day precisions were 7 and 12%, respectively. The detection and quantitation limits in dog plasma were 0.024 and 0.078 microg/ml, respectively.

100 项与 Alinastine 相关的药物交易

登录后查看更多信息